Blood levels of TNF-, IL-10, and IL-12 in idiopathic sudden sensorineural hearing loss

Objectives/Hypothesis To investigate the blood levels of TNF-, IL-10, and IL-12 in the idiopathic sudden sensorineural hearing loss patients, and the change of these cytokine levels after treatment. Study Design Prospective clinical trial. Methods Twenty-three patients with idiopathic sudden sensorineural hearing loss and 20 healthy people were selected as study and control groups. Blood samples for TNF-, IL-10, and IL-12 were taken before treatment and 6 weeks after treatment. The study group was given combined treatment including dexamethasone, heparin, pentoxifyline, vitamin B1, and B6 for 10 days, and was divided into two groups: treatment responders and treatment nonresponders. The treatment responders group was also divided into three groups according to most accepted criteria for improvement in the literature. Audiograms were taken before treatment and 6 weeks after treatment to determine the response to the treatment. Results There was no significant difference between pre- and posttreatment values of IL-10 and IL-12 in all study groups (P > 0.05). There was also no significant difference between pre- and posttreatment values of TNF- in treatment responders (P > 0.05). Treatment nonresponders had more elevated posttreatment values of TNF- than pretreatment values (P < 0.05). Conclusion IL-10 and IL-12 may not play a critical role in idiopathic sudden sensorineural hearing loss. But our data supports the role of TNF- in the pathophysiology of idiopathic sudden sensorineural hearing loss, and TNF- receptor blockers may have benefits in these patients. Level of Evidence 3B. Laryngoscope, 2013

Yazar Demirhan, Erhan
Eskut, Neslihan Purdas
Zorlu, Yasar
Cukurova, Ibrahim
Tuna, Gamze
Kirkali, Fatos Guldal
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/2167
Tek Biçim Adres 10.1002/lary.23907
Konu Başlıkları Idiopathic
hearing loss
cytokine
interleukin
TNF-
IL-10
IL-12
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı LARYNGOSCOPE
Dergi Cilt Bilgisi 123
Dergi Sayısı 7
Sayfalar 1778 - 1781
Yayın Yılı 2013
Eser Adı
[dc.title]
Blood levels of TNF-, IL-10, and IL-12 in idiopathic sudden sensorineural hearing loss
Yazar
[dc.contributor.author]
Demirhan, Erhan
Yazar
[dc.contributor.author]
Eskut, Neslihan Purdas
Yazar
[dc.contributor.author]
Zorlu, Yasar
Yazar
[dc.contributor.author]
Cukurova, Ibrahim
Yazar
[dc.contributor.author]
Tuna, Gamze
Yazar
[dc.contributor.author]
Kirkali, Fatos Guldal
Yayın Yılı
[dc.date.issued]
2013
Yayıncı
[dc.publisher]
WILEY
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Objectives/Hypothesis To investigate the blood levels of TNF-, IL-10, and IL-12 in the idiopathic sudden sensorineural hearing loss patients, and the change of these cytokine levels after treatment. Study Design Prospective clinical trial. Methods Twenty-three patients with idiopathic sudden sensorineural hearing loss and 20 healthy people were selected as study and control groups. Blood samples for TNF-, IL-10, and IL-12 were taken before treatment and 6 weeks after treatment. The study group was given combined treatment including dexamethasone, heparin, pentoxifyline, vitamin B1, and B6 for 10 days, and was divided into two groups: treatment responders and treatment nonresponders. The treatment responders group was also divided into three groups according to most accepted criteria for improvement in the literature. Audiograms were taken before treatment and 6 weeks after treatment to determine the response to the treatment. Results There was no significant difference between pre- and posttreatment values of IL-10 and IL-12 in all study groups (P > 0.05). There was also no significant difference between pre- and posttreatment values of TNF- in treatment responders (P > 0.05). Treatment nonresponders had more elevated posttreatment values of TNF- than pretreatment values (P < 0.05). Conclusion IL-10 and IL-12 may not play a critical role in idiopathic sudden sensorineural hearing loss. But our data supports the role of TNF- in the pathophysiology of idiopathic sudden sensorineural hearing loss, and TNF- receptor blockers may have benefits in these patients. Level of Evidence 3B. Laryngoscope, 2013
Açıklama
[dc.description]
WOS: 000320784300036
Açıklama
[dc.description]
PubMed: 23382065
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Idiopathic
Konu Başlıkları
[dc.subject]
hearing loss
Konu Başlıkları
[dc.subject]
cytokine
Konu Başlıkları
[dc.subject]
interleukin
Konu Başlıkları
[dc.subject]
TNF-
Konu Başlıkları
[dc.subject]
IL-10
Konu Başlıkları
[dc.subject]
IL-12
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0023-852X
ISSN
[dc.identifier.issn]
1531-4995
İlk Sayfa Sayısı
[dc.identifier.startpage]
1778
Son Sayfa Sayısı
[dc.identifier.endpage]
1781
Dergi Adı
[dc.relation.journal]
LARYNGOSCOPE
Dergi Sayısı
[dc.identifier.issue]
7
Dergi Cilt Bilgisi
[dc.identifier.volume]
123
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1002/lary.23907
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/2167
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
124
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
07 Haziran 2024 22:20
Google Kontrol
Tıklayınız
treatment values sudden hearing sensorineural idiopathic groups responders posttreatment patients significant between difference divided nonresponders before levels blockers pathophysiology receptor benefits Evidence Laryngoscope supports Conclusion critical Treatment elevated pretreatment Results Objectives/Hypothesis response Methods control selected
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms